LPCNHIGH SIGNALFINANCIAL10-K

LPCN experienced a dramatic financial deterioration with revenue collapsing 82% from $11.2M to $2.0M while swinging from $8K profit to a $9.6M loss.

The company appears to have transitioned from generating meaningful revenue to a much more constrained financial position, suggesting either the loss of a major revenue source or completion of a significant contract. The 36% increase in outstanding shares (from 5.35M to 7.3M) indicates recent equity dilution, likely to fund operations given the negative cash flow deterioration.

Comparing 2026-03-10 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

LPCN's financials show severe deterioration across all key metrics, with revenue plummeting 82% and the company swinging from modest profitability to nearly $10M in losses and negative operating cash flow. While total debt decreased significantly by 67%, this was offset by stockholders' equity declining 31% and current liabilities increasing 67%, suggesting the company burned through cash and took on short-term obligations. The combination of collapsing revenue, mounting losses, and share dilution signals a company in financial distress that may struggle with near-term viability without additional funding or revenue recovery.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-115371.9%
$8K→-$9.6M

Net income declined 115371.9% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-797.9%
-$1.2M→-$10.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Operating Cash Flow
Cash Flow
-699.3%
-$1.2M→-$9.8M

Operating cash flow fell 699.3% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
+584.2%
$13K→$90K

Capital expenditure jumped 584.2% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
-86.7%
$203K→$27K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
-82.3%
$11.2M→$2.0M

Revenue declined 82.3% — significant demand weakness or market share loss warrants investigation.

Total Liabilities
Balance Sheet
+67.1%
$1.5M→$2.5M

Liabilities grew 67.1% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+67.1%
$1.5M→$2.5M

Current liabilities surged 67.1% — significant near-term obligations; verify ability to meet short-term debt.

Total Debt
Balance Sheet
-66.7%
$5.0M→$1.7M

Debt reduced 66.7% — deleveraging strengthens balance sheet and reduces financial risk.

Stockholders Equity
Balance Sheet
-31.1%
$21.0M→$14.5M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

LANGUAGE CHANGES
NEW — 2026-03-10
PRIOR — 2025-03-13
ADDED
As of March 9, 2026, the registrant had 7,299,687 shares of common stock outstanding.
We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances , except as otherwise required by law.
We are a biopharmaceutical company focused on leveraging our proprietary technology platform to develop innovative products with effective oral delivery of previously difficult to deliver molecules.
The license agreement is for the development and commercialization of our product, TLANDO, an oral treatment indicated for testosterone replacement therapy ( testosterone replacement therapy or TRT ) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism) comprised of testosterone undecanoate ( testosterone undecanoate or TU ) and any post-marketing studies required by the United States Food and Drug Administration ( FDA ) will also be the responsibility of Verity.
In April 2025, we entered into a License and Supply Agreement (the Ach License Agreement ) with Ach , pursuant to which we granted to Ach an exclusive license to commercialize TLANDO with respect to the field, specific to Brazil (the Ach Territory ).
+7 more — sign up free →
REMOVED
As of March 11, 2025, the registrant had 5,350,356 shares of common stock outstanding.
We undertake no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law .
We are a biopharmaceutical company focused on leveraging our proprietary Lip ral platform to develop differentiated products through the oral delivery of previously difficult to deliver molecules.
We entered into a license agreement for the development and commercialization of our product candidate, TLANDO , an oral treatment indicated for testosterone replacement therapy ( testosterone replacement therapy or TRT ) in adult males for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic hypogonadism) comprised of testosterone undecanoate ( testosterone undecanoate or TU ).
Any post-marketing studies required by the United States Food and Drug Administration ( FDA ) will also be the responsibility of our Licensee, Verity.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →